Fibroblast Growth Factor Receptor Inhibitor–Associated Retinopathy

This case report details off-label treatment of a patient’s gastric adenocarcinoma with erdafitinab.

Loading next page...

References (6)

Lélia Carvalho, Sandra Avelar, A. Haslam, J. Gill, V. Prasad (2019)
Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
JAMA Network Open, 2
Marissa Weber, Michelle Liang, K. Flaherty, J. Heier (2016)
Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer.
JAMA ophthalmology, 134 8
S. Schoenberger, Stephen Kim (2013)
Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma
Case Reports in Ophthalmological Medicine, 2013
Y. Loriot, A. Necchi, S. Park, J. García-Donas, R. Huddart, E. Burgess, M. Fleming, A. Rezazadeh, B. Mellado, S. Varlamov, M. Joshi, I. Durán, S. Tagawa, Y. Zakharia, B. Zhong, K. Stuyckens, A. Santiago-Walker, P. Porre, Anne O’Hagan, A. Avadhani, A. Siefker-Radtke (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
The New England journal of medicine, 381 4
E. Dijk, C. Herpen, M. Marinkovic, J. Haanen, D. Amundson, G. Luyten, M. Jager, E. Kapiteijn, J. Keunen, G. Adamus, C. Boon (2015)
Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.
Ophthalmology, 122 9
R. Noll, S. Leijen, G. Neuteboom, J. Beijnen, J. Schellens (2013)
Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities.
Cancer treatment reviews, 39 6